Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Prevalence and factors involved in discordant responses to highly active antiretroviral treatment in a closely followed cohort of treatment-naïve HIV-infected patients.

Molina-Pinelo S, Leal M, Soriano-Sarabia N, Gutiérrez S, Fernandez G, Muñoz-Fernández MA, Lissen E, Vallejo A.

J Clin Virol. 2005 Jun;33(2):110-115.

PMID:
15952251
2.

"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

Wood E, Hogg RS, Yip B, Tyndall MW, Sherlock CH, Harrigan RP, O'Shaughnessy MV, Montaner JS.

J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):159-66.

PMID:
12045678
3.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
4.

Discordant Treatment Responses to Combination Antiretroviral Therapy in Rwanda: A Prospective Cohort Study.

Kayigamba FR, Franke MF, Bakker MI, Rodriguez CA, Bagiruwigize E, Wit FW, Rich ML, Schim van der Loeff MF.

PLoS One. 2016 Jul 20;11(7):e0159446. doi: 10.1371/journal.pone.0159446. eCollection 2016.

5.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
6.

Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration.

Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, Nash D, Sprinz E, Dabis F, Harrison LH, Schechter M.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):52-9.

PMID:
17460471
7.

Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study.

Gilson RJ, Man SL, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K, Gazzard B, Orkin C, Pillay D, Schwenk A, Johnson M, Easterbook P, Walsh J, Fisher M, Leen C, Anderson J, Sabin CA; UK Collaborative HIV Cohort Study Group.

HIV Med. 2010 Feb;11(2):152-60. doi: 10.1111/j.1468-1293.2009.00755.x. Epub 2009 Sep 1.

8.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
9.

Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.

Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J, Fisher M, Orkin C, Schwenk A, Gilson R, Easterbrook P, Delpech V, Sabin CA; UK CHIC Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):202-5.

PMID:
17971709
10.

Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.

Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance.

Clin Infect Dis. 2009 May 1;48(9):1296-305. doi: 10.1086/598502.

PMID:
19331585
11.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

PMID:
15909251
12.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
13.

Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011.

Martin DA, Luz PM, Lake JE, Clark JL, Veloso VG, Moreira RI, Cardoso SW, Klausner JD, Grinsztejn B.

BMC Infect Dis. 2014 Jun 11;14:322. doi: 10.1186/1471-2334-14-322.

14.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

15.

CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.

McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.

Clin Infect Dis. 2005 Dec 1;41(11):1662-70. Epub 2005 Oct 19.

PMID:
16267741
16.

Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.

De Luca M, Miccinesi G, Chiappini E, Zappa M, Galli L, De Martino M.

Int J Immunopathol Pharmacol. 2005 Oct-Dec;18(4):729-35.

PMID:
16388722
17.

A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.

Piroth L, Fournel I, Mahy S, Yazdanpanah Y, Rey D, Rabaud C, Faller JP, Hoen B, Fardeheb M, Quantin C, Chavanet P, Binquet C; Groupe InterCOrevih du Nord-Est.

Epidemiol Infect. 2011 Dec;139(12):1835-44. doi: 10.1017/S0950268810002980. Epub 2011 Jan 14.

PMID:
21232172
18.

Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.

de Truchis P, Force G, Welker Y, Mechali D, Pulik M, Chemlal K, Rouveix E, Devidas A, Praindhui D, Mamet JP; CNAF3008 Group.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):178-82.

PMID:
12394796
19.

Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50.

PMID:
15220701
20.

Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort.

Servais J, Schmit JC, Arendt V, Lambert C, Staub T, Robert I, Fontaine E, Plesséria JM, Burgy C, Kirpach P, Schneider F, Hemmer R.

HIV Clin Trials. 2000 Sep-Oct;1(2):17-24.

PMID:
11590494

Supplemental Content

Support Center